Farxiga (Dapagliflozin) in Your 40s: What Every Perimenopausal Woman Should Know

What Farxiga Actually Does (And Why Your 40s Matter)

Dapagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) protein in your kidney tubules, forcing roughly 60 to 80 grams of glucose out in your urine each day rather than reabsorbing it back into blood. The result is lower blood glucose, a mild osmotic diuresis (more urine), a small but real drop in blood pressure, and a modest reduction in body weight of around 2 to 4 kg on average over 24 weeks in clinical trials.

Your 40s are not a neutral backdrop for this mechanism. Perimenopause typically begins between ages 40 and 51, with the average age of onset around 47, according to data from the SWAN study. During this window, estrogen fluctuates wildly before ultimately falling. That hormonal volatility changes nearly every system Farxiga touches: your glucose metabolism, your urogenital microbiome, your bone turnover rate, and your cardiovascular risk trajectory.

Understanding those intersections is not optional background reading. It is the clinical information that should shape your conversation with your prescriber.

How Perimenopause Changes Your Metabolic Risk

Estrogen Loss and Insulin Resistance

Estrogen is metabolically protective. It improves insulin sensitivity in skeletal muscle, supports pancreatic beta-cell function, and reduces visceral fat accumulation. As estrogen levels drop during perimenopause, insulin resistance tends to rise. A 2020 analysis published in Menopause found that the menopause transition independently increases insulin resistance, separate from the effect of aging or weight gain.

This matters for Farxiga because you may be starting this drug at a point when your underlying metabolic field is already shifting. The drug will still work, but your prescriber should know you are perimenopausal when assessing your glycemic targets and monitoring plan.

Central Weight Gain and SGLT2 Benefit

The fat redistribution of perimenopause, specifically the shift from gynoid (hips and thighs) to central (abdominal) fat storage, increases your cardiometabolic risk. Farxiga reduces visceral adiposity more than subcutaneous fat in trials, making it a reasonable choice for perimenopausal women with T2D and central weight gain. The DECLARE-TIMI 58 trial enrolled 17,160 patients with T2D or established cardiovascular disease and showed that dapagliflozin reduced hospitalization for heart failure by 27% compared to placebo. Women made up about 37% of that cohort, a meaningful but still minority share.

PCOS in Your 40s

If you have polycystic ovary syndrome, you may carry insulin resistance and elevated androgen levels well into your 40s. SGLT2 inhibitors are not FDA-approved for PCOS, but small studies suggest they may reduce fasting insulin and androgen levels. The evidence is preliminary, and no large randomized controlled trial has specifically studied dapagliflozin in women with PCOS across the perimenopause transition.

A practical framework for perimenopausal women considering Farxiga:

1. Confirm your current menstrual pattern with your prescriber. Irregular cycles can mask both early pregnancy and anovulation.
2. Establish a baseline HbA1c and fasting glucose, because the perimenopausal metabolic shift may mean your numbers look worse than they did two years ago, not because of diet but because of estrogen.
3. Ask specifically about UTI and yeast infection history. If you have had more than two genitourinary infections in the past year, that history should factor into the prescribing decision.
4. Discuss bone density. If you have not had a DEXA scan and you have any bone-density risk factors, perimenopause plus an SGLT2 inhibitor is a reasonable trigger for one.

Urogenital Infections: The Risk That Hits Harder in Perimenopause

This is the side effect most likely to affect your quality of life on Farxiga, and perimenopause amplifies it substantially.

Why Your 40s Raise Your Baseline Risk

Falling estrogen thins the vaginal epithelium and shifts the vaginal pH upward, reducing Lactobacillus dominance and making the genitourinary tract more susceptible to both yeast and bacterial colonization. At the same time, Farxiga increases urinary glucose concentration, providing a growth medium for Candida species in the vulvovaginal area.

In the DECLARE-TIMI 58 trial, genital mycotic infections occurred in 6.4% of women on dapagliflozin versus 1.4% on placebo, a roughly 4-fold increase. Urinary tract infections occurred in 6.4% of women on dapagliflozin versus 5.8% on placebo, a smaller but real difference.

Women already experiencing genitourinary syndrome of menopause (GSM), which can begin in perimenopause, face a compounding problem. Vaginal atrophy-related microbiome disruption plus glucosuria is a meaningful one-two combination that most Farxiga trial summaries do not address directly because the trials did not stratify by menopausal status.

What to Do About It

Local vaginal estrogen (cream, ring, or tablet) reduces vaginal pH and restores the Lactobacillus-dominant environment. If you are on systemic hormone therapy (HT) for perimenopausal symptoms, that also helps. Tell your prescriber you are perimenopausal before starting Farxiga, and discuss whether local or systemic estrogen is appropriate for you alongside the SGLT2 inhibitor.

Practical hygiene: urinate after sexual activity, wipe front to back, avoid tight synthetic underwear. These are basic but do reduce recurrence rates in observational data.

Heart and Kidney Benefits: The Evidence in Women

Heart Failure

Farxiga is approved for heart failure with reduced ejection fraction (HFrEF) based on the DAPA-HF trial, which showed a 26% relative risk reduction in the composite of worsening heart failure or cardiovascular death versus placebo. Women made up 23% of DAPA-HF participants. Subgroup analyses did not show a significant sex interaction, meaning the benefit appeared consistent across sexes, though the study was not powered to detect sex-specific differences.

For heart failure with preserved ejection fraction (HFpEF), the DELIVER trial showed dapagliflozin reduced worsening heart failure events and cardiovascular death by 18% relative to placebo. HFpEF disproportionately affects women, particularly after menopause, making this an area of growing clinical relevance. Women in your 40s with early cardiometabolic risk factors, including hypertension or obesity, may be starting on a trajectory toward HFpEF in their 50s and 60s.

Chronic Kidney Disease

The DAPA-CKD trial enrolled patients with CKD regardless of diabetes status and showed a 39% relative risk reduction in the composite of sustained eGFR decline, end-stage kidney disease, or renal or cardiovascular death compared to placebo. Women made up about 33% of participants. If you have CKD in addition to T2D or heart failure, this drug has strong evidence for kidney protection that extends beyond glucose control.

Bone Health: A Flag You Cannot Ignore at This Life Stage

Perimenopausal bone loss accelerates starting two to three years before the final menstrual period, driven by falling estrogen. The rate of cortical bone loss during this window can exceed the rate seen in early postmenopause, according to SWAN bone density data.

SGLT2 inhibitors have a complicated relationship with bone. An FDA safety review flagged canagliflozin (a related SGLT2 inhibitor) for increased fracture risk. For dapagliflozin specifically, the DECLARE-TIMI 58 trial found no significant increase in fracture rates compared to placebo. Still, the class-level concern means you and your prescriber should take inventory of your bone health when starting any SGLT2 inhibitor in your 40s.

Ask about:

• Baseline DEXA scan if you have risk factors (low body weight, smoking, family history of osteoporosis, prolonged low estrogen)
• Whether systemic hormone therapy is also appropriate for you to protect bone during the perimenopausal window
• Calcium and vitamin D adequacy

Euglycemic DKA: A Rare but Serious Risk Women Need to Know

Euglycemic diabetic ketoacidosis (DKA) is a state of ketoacidosis where blood glucose is not dramatically elevated, making it easy to miss. SGLT2 inhibitors increase the risk of euglycemic DKA, particularly when you are fasting, ill, or following a very low-carbohydrate diet.

Women may face a modestly higher baseline risk of DKA with SGLT2 inhibitors than men, based on FDA adverse event data, though the absolute risk remains low. The FDA issued a safety communication on this risk and recommends stopping dapagliflozin before surgery or prolonged fasting.

If you are following a ketogenic or very low carbohydrate diet for perimenopausal weight management, tell your prescriber. That combination with Farxiga raises your euglycemic DKA risk materially.

Symptoms to watch for: nausea, vomiting, abdominal pain, malaise, or shortness of breath, even if your blood sugar reads normal. Go to the emergency room. Do not wait.

Pregnancy, Lactation, and Contraception: Non-Negotiable Information

This section is mandatory for any drug article at WomanRx, and for dapagliflozin it carries real urgency for women in their 40s who may still be ovulating, even if their cycles are irregular.

Pregnancy Safety

Farxiga is contraindicated during the second and third trimesters of pregnancy. Animal studies at exposures relevant to human dosing showed kidney dysplasia and reduced fetal weight. The FDA prescribing information states: "Dapagliflozin is not recommended during the first trimester of pregnancy due to the potential for adverse effects on fetal kidney development."

Human data are extremely limited. There are no well-controlled trials of dapagliflozin in pregnant women. This is not a reassuring data gap. It is an absence of safety evidence in a category where the animal signals are concerning.

Perimenopause does not equal infertility. Women in their 40s can and do conceive. Ovulation can occur during irregular perimenopausal cycles without reliable prediction. If you are having sex with a male partner and are not using highly effective contraception, dapagliflozin should be prescribed with a clear contraception plan in place.

Lactation

Farxiga is not recommended during breastfeeding. Animal studies showed tubular dilation and renal pelvis distension in juvenile rats exposed to dapagliflozin during the postnatal period. The kidney matures postnatally in humans as well. Human lactation transfer data are not available. The prescribing information recommends against use during breastfeeding given the risk of renal toxicity in a developing infant.

If you are in your early 40s and postpartum, have this conversation explicitly with your prescriber. Do not assume that "this is a diabetes drug" means breastfeeding is fine.

Contraception Guidance

If you are taking Farxiga and could become pregnant:

• Use highly effective contraception (hormonal IUD, copper IUD, implant, or combined oral contraceptive pill if not contraindicated for you)
• If you are using a combined oral contraceptive pill, be aware that Farxiga does not significantly interact with estrogen-progestin pharmacokinetics based on current data
• Discuss your contraceptive plan at every Farxiga follow-up visit until you are confirmed postmenopausal (typically defined as 12 consecutive months without a menstrual period)

Who This Drug Is Right For in Your 40s (And Who Should Think Twice)

Good Candidates in the Perimenopausal Window

• Women with T2D who have not reached glycemic targets on metformin alone
• Women with T2D and established cardiovascular disease or multiple CV risk factors (hypertension, central obesity, dyslipidemia)
• Women with heart failure (reduced or preserved ejection fraction) regardless of diabetes status
• Women with CKD (eGFR 25 to 75 mL/min/1.73 m² for the kidney indication) regardless of diabetes status
• Women with PCOS and insulin resistance, as an off-label consideration in consultation with a reproductive endocrinologist

Think Carefully If You

• Have a history of recurrent UTIs or vulvovaginal yeast infections and are not on local vaginal estrogen or systemic HT
• Have significant genitourinary syndrome of menopause symptoms without current treatment
• Follow a ketogenic or very low carbohydrate diet without close medical supervision
• Have an eGFR below 25 mL/min/1.73 m² (the drug becomes ineffective for glucose lowering at low eGFR, though kidney and heart failure indications may still apply per prescribing information)
• Are planning pregnancy or are not using reliable contraception
• Are postpartum and breastfeeding

Dosing, Monitoring, and What to Track

Standard Dose

Dapagliflozin is taken once daily, with or without food. The starting dose for T2D is 5 mg daily, which can be increased to 10 mg daily if additional glycemic control is needed and tolerated. For heart failure and CKD indications, the approved dose is 10 mg once daily.

No dose adjustment is required based on age alone in your 40s. Renal function does affect dosing: if your eGFR falls below 45 mL/min/1.73 m², dapagliflozin is less effective for glucose lowering (though heart failure and CKD benefits persist at lower eGFR ranges per the label).

Monitoring Schedule

Your prescriber should check:

| Parameter | Frequency | |---|---| | HbA1c | Every 3 months until stable, then every 6 months | | eGFR and serum creatinine | Before starting, at 3 months, then annually | | Blood pressure | Each visit (Farxiga has a mild BP-lowering effect) | | Weight | Each visit | | Genital/urinary symptoms | At each visit; do not wait for your annual exam | | Bone density (DEXA) | Baseline if risk factors present; every 2 years if concern |

The Evidence Gap: What We Don't Know About Farxiga in Perimenopausal Women

Women have been historically under-represented in cardiovascular and metabolic drug trials. The DAPA-HF trial enrolled only 23% women. DECLARE-TIMI 58 enrolled 37%. DAPA-CKD enrolled 33%. None of these trials stratified results by menopausal status or reported outcomes specifically in perimenopausal versus postmenopausal versus premenopausal women.

This means the specific question of "how does dapagliflozin perform in a woman transitioning through perimenopause" is answered largely by inference, not direct data. We extrapolate from the overall sex-based subgroup analyses, from what we know about perimenopausal physiology, and from the drug's mechanism.

The Menopause Society's 2023 position statement on menopause and cardiometabolic health does not specifically address SGLT2 inhibitors but emphasizes that individualized risk assessment is required for any cardiometabolic intervention during the menopause transition. That principle applies directly here.

This is not a reason to avoid the drug. It is a reason to be monitored closely, to report any new symptoms promptly, and to work with a prescriber who takes your perimenopausal status seriously as a clinical variable.

Direct Quotes From Guideline Documents

The FDA prescribing information for Farxiga states: "There are no data on the presence of dapagliflozin in human milk, the effects on the breastfed infant, or the effects on milk production."

The 2023 ADA Standards of Care in Diabetes recommend SGLT2 inhibitors for adults with T2D and established cardiovascular disease, heart failure, or CKD "regardless of HbA1c or individualized HbA1c target," a recommendation that applies to women in their 40s who meet those criteria.